Pneumocystis jirovecii pneumonia in intensive care units: a multicenter study by ESGCIP and EFISG
Authors' conclusion
PJP in critically ill patients admitted to ICU is nowadays most encountered in non-HIV patients. Serum BDG when used in combination with respiratory Pneumocystis PCR could help improve the certainty of PJP diagnosis.
Study context
- Population
- Critically ill intensive care unit (ICU) patients subjected to diagnostic workup for Pneumocystis jirovecii pneumonia (PJP)
- Participants
- 600 patients
- Outcome
- Characteristics of ICU patients subjected to diagnostic workup for PJP
Main finding
As reported in the abstract
Characteristics of tested ICU patients
- Presumptive/proven PJP
- 19.2%
- HIV infection
- 8.8%
- Hematological malignancy
- 23.2%
- Solid tumor
- 16.2%
- Inflammatory diseases
- 15.5%
- Solid organ transplants
- 10.0%
Observational data: associations, not effects.
Secondary outcomes
Variables associated with PJP (multivariable analysis)
| OR (95% CI) | P value | ||
|---|---|---|---|
| AIDS | 3.31 (1.13–9.64) | P = 0.029 | |
| Non-Hodgkin lymphoma | 3.71 (1.23–11.18) | P = 0.020 | |
| Vasculitis | 5.95 (1.07–33.22) | P = 0.042 | |
| Metastatic solid tumor | 4.31 (1.76–10.53) | P = 0.001 | |
| Bilateral ground glass on CT | 2.19 (1.01–4.78) | P = 0.048 | |
| Increasing lymphocyte cell countInverse association | 0.64 (0.42–1.00) | P = 0.049 | |
| 0.050.21520Odds ratio (log scale) |
PPV for PJP diagnosis
PPV
Cumulative mortality in presumptive/proven PJP
- 30-day mortality
- 52%
- 90-day mortality
- 67%
Original publication
Pneumocystis jirovecii pneumonia in intensive care units: a multicenter study by ESGCIP and EFISG. Crit Care. Published 24 August 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →